PDCD1 and autoimmune pancreatitis: Lastly, since humans and mice may have different tolerance to AIP priming or subsequent combination of PD-1 and CTLA-4 blockade, translation of the proposed priming strategy to clinical testing would require careful monitoring for potential toxicities associated with the combination therapy.